We also demonstrated the molecular mechanism by which the mTOR inhibitor rapamycin arrests the aberrant epithelial proliferation in the ADPKD kidney, which resulted de novo from PC2 dysfunction. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.